 EMERYVILLE, Calif., March 11, 2021 GLOBE NEWSWIRE -- Gritstone Oncology, Inc. Nasdaq: GRTS, a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, today reported financial results for the fourth quarter and full year ended December 31, 2020 and reviewed business highlights. 